quarterly, page-4

Yokka, surely you have read the previous ones, this is standard and shouldn't be treated as anything other than that, standard. We have the ATM to tap if it was needed and the debt funding to come for expansion etc.

Last year (half yearly) they wrote:

"The Company will need additional funding in the future to support its operations and capital expenditure requirements.
Management has identified several possible funding strategies, which may or may not be available. In addition to sales of its Unitract and Unifill syringe products to pharmaceutical companies with which the Company has existing commercial relationships, the Company is also in discussions with additional pharmaceutical companies pertaining to the Unifill syringe and other pipeline products. Should the Company enter into commercial relationships relating to the industrialization, commercial supply or preferred use of a device within a particular therapeutic market, the Company may receive additional funding or revenue streams. The Company may also seek to raise additional funds through the sale of additional debt or equity securities. There can be no assurance that any such funding will be available when needed or on acceptable terms. These various factors raise substantial doubt about the Company’s ability to continue as a
going concern."